JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to kno...
JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
JAK inhibitors (JAKinibs) have been approved for several immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (axSpA), and non-radiographic axSpA. Although they have been proved to be very effective, some safety concerns have emerged. These mainly pertain to their profile regard...
Alternative Titles
Full title
JAK inhibitors, cardiovascular and thromboembolic events: what we know and what we would like to know
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2754046062
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2754046062
Other Identifiers
ISSN
0770-3198
E-ISSN
1434-9949
DOI
10.1007/s10067-022-06471-x
